StreetInsider.com News Articles

Form 4 Vaxcyte, Inc. For: Jun 01 Filed by: Wassil Jim

Wed, 03 Jun 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260603/26600017.html

Form 4 Vaxcyte, Inc. For: Jun 01 Filed by: Wassil Jim

Wed, 03 Jun 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260603/26600017.html

Vaxcyte begins first human trial of Group A strep vaccine candidate

Tue, 02 Jun 2026 16:05:14 -0400

Vaxcyte Inc. (NASDAQ: PCVX) dosed the first participant in a Phase 1 study evaluating VAX-A1, its investigational vaccine candidate designed to prevent disease caused by Group A Streptococcus. The company expects to announce topline data from the study in the second half of 2027.

The randomized, double-blind, placebo-controlled study will evaluate VAX-A1 in approximately 80 healthy adults aged 18 to 40 years. The two-stage, dose-escalation trial's primary objective is assessing safety and tolerability, with a secondary objective of evaluating immune responses.

Stage 1 will enroll approximately 12 participants to test three dose levels against placebo. Following a safety review by an independent

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Tue, 02 Jun 2026 16:05:00 -0400

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus

Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses

Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Significant Public Health Burden

SAN CARLOS, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Tue, 02 Jun 2026 16:05:00 -0400

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus

Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to Assess Antigen-Specific Immune Responses

Group A Strep Is Responsible for Approximately 800 Million New Cases of Illness and More Than 600,000 Deaths Annually Worldwide, with No Approved Vaccine and Significant Public Health Burden

SAN CARLOS, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to

Form 144 Vaxcyte, Inc. Filed by: Wassil Jim

Mon, 01 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260601/26584115.html

Form 144 Vaxcyte, Inc. Filed by: Wassil Jim

Mon, 01 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260601/26584115.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 15 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26507296.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 15 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260515/26507296.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26502883.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26502883.html

Form 10-Q Vaxcyte, Inc. For: Mar 31

Wed, 06 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260506/26443934.html

Form 10-Q Vaxcyte, Inc. For: Mar 31

Wed, 06 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260506/26443934.html

Form 8-K Vaxcyte, Inc. For: May 06

Wed, 06 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260506/26443738.html

Form 8-K Vaxcyte, Inc. For: May 06

Wed, 06 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260506/26443738.html

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Wed, 06 May 2026 16:05:00 -0400

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027

Enrollment Completed for VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027

Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1,

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Wed, 06 May 2026 16:05:00 -0400

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027

Enrollment Completed for VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027

Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1,

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400
si-local-file:///var/storage/secattach/20260506/26441795.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400
si-local-file:///var/storage/secattach/20260506/26441795.html

Form 4 Vaxcyte, Inc. For: May 01 Filed by: Wassil Jim

Fri, 01 May 2026 17:38:00 -0400
si-local-file:///var/storage/secattach/20260501/26419002.html

Form 4 Vaxcyte, Inc. For: May 01 Filed by: Wassil Jim

Fri, 01 May 2026 17:38:00 -0400
si-local-file:///var/storage/secattach/20260501/26419002.html

Form 144 Vaxcyte, Inc. Filed by: Wassil Jim

Fri, 01 May 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260501/26417944.html

Form 144 Vaxcyte, Inc. Filed by: Wassil Jim

Fri, 01 May 2026 16:18:00 -0400
si-local-file:///var/storage/secattach/20260501/26417944.html

Form SCHEDULE 13G Vaxcyte, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Thu, 30 Apr 2026 14:24:00 -0400
si-local-file:///var/storage/secattach/20260430/26405892.html

Form SCHEDULE 13G Vaxcyte, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Thu, 30 Apr 2026 14:24:00 -0400
si-local-file:///var/storage/secattach/20260430/26405892.html